• shareIcon

HIV Drug may Prevent Cervical Cancer

Latest By Himanshu Sharma , Onlymyhealth editorial team / Feb 19, 2014
HIV Drug may Prevent Cervical Cancer

The study found that drug wiped out pre-cancerous cells in 90 per cent of women - with no side-effects. They believed that in the future, women could be prescribed a drug to use at home, instead of enduring a biopsy or surgery.

According to a study conducted at the University of Manchester, HIV drug lopinavir has been shown to kill-off the human papilloma virus (HPV) that leads to cervical cancer.

cervical cancer treatmentThe study found that drug wiped out pre-cancerous cells in 90 per cent of women - with no side-effects. They believed that in the future, women could be prescribed a drug to use at home, instead of enduring a biopsy or surgery.

The trial took place at the Kenyatta National Hospital (KNH) in Nairobi, Kenya. A panel of researchers examined 40 women with low-grade and high-grade stage pre-cancerous disease of the cervix. The antiviral drug lopinavir is used orally to treat HIV but it was applied directly to the cervix as a pessary in the trial.

The women were treated with one capsule of the antiviral drug twice a day for two weeks. Repeat cervical smears showed a marked improvement within one month of the treatment.

 

 

(Source - Daily Mail)

 

Read more Health News.

 

 

Disclaimer

All possible measures have been taken to ensure accuracy, reliability, timeliness and authenticity of the information; however Onlymyhealth.com does not take any liability for the same. Using any information provided by the website is solely at the viewers’ discretion. In case of any medical exigencies/ persistent health issues, we advise you to seek a qualified medical practitioner before putting to use any advice/tips given by our team or any third party in form of answers/comments on the above mentioned website.

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK